hotspot -WSS

hotspot

author：entertainment 2025-10-02 00:39:59 - browse：7597

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： UnitedHealth, Optum discontinue NaviHealth name

focus

WSS

STAT Summit: How researchers deal with rejection

Merck, Daiichi strike cancer drug pact worth up to $22 billion

The problems with dementia villages

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Study points to new risk in gene therapy death of Terry Horgan

Smaller biotechs seek to piggyback on weight loss drug boom

Wikipedia

hotspot

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

RSV injection headlines need to be accurate for good uptake

Novavax promises a turnaround & Lilly roils the obesity market

STAT Summit: Ending the crisis of Black deaths in the U.S.

Jerome Adams on the need for new antivirals for Covid

STAT Readout Newsletter: Biotech news today

Medical records are filled with copy

The problems with dementia villages

ChatGPT in medicine: STAT answers readers' burning questions

Roche drug slashes death risk in early

focus

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

STAT Readout: Friday, Oct. 20 biotech updates

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Will an HIV vaccine ever be a reality?

ADCs take center stage as promising cancer treatments

ADCs take center stage as promising cancer treatments

Wikipedia

focus

focus

focus